Table 1.
Clinicobiological parameters of the studied cohort.
| HR− | HR+ | |||||
|---|---|---|---|---|---|---|
| Ki-67 ≤ 20% (Prolif−) (n = 19) |
Ki-67 ≥ 30% (Prolif+) (n = 29) |
p | Ki-67 ≤ 20% (Prolif−) (n = 51) |
Ki-67 ≥ 30% (Prolif+) (n = 41) |
p | |
| Age (years) * | 62.5 [56.0–69.0] | 54.4 [43.0–66.0] | 0.08 | 64.1 [56.0–72.5] | 56.2 [48.0–66.0] | 0.003 |
| BMI (kg m−2) * | 24.7 [21.8–27.3] | 25.2 [22.2–27.1] | 0.66 | 25.4 [22.7–27.5] | 26.1 [21.9–28.8] | 0.67 |
| Menopausal status ** | 17 (89%) | 21 (72%) | 0.15 | 43 (84.3%) | 24 (58.8%) | 0.006 |
| Normolipidemic treatments | 3 (16%) | 4 (14%) | 0.85 | 5 (9.8%) | 5 (12%) | 0.71 |
| Type of Cancer ** | 0.29 | 0.01 | ||||
| Invasive Carcinoma of No Special Type (Ductal) | 16 (84%) | 28 (97%) | 51 (100%) | 36 (88%) | ||
| Invasive Lobular Carcinoma | 2 (11%) | 1 (3%) | 0 | 5 (12%) | ||
| Histoprognostic Grade ** | <0.001 | <0.001 | ||||
| Grade I | 0 | 0 | 21 (41.2%) | 0 | ||
| Grade II | 17 (89%) | 3 (10.3%) | 26 (51%) | 6 (14.6%) | ||
| Grade III | 2 (11%) | 26 (89.7%) | 4 (7.8%) | 35 (85.4%) | ||
| HER2+ | 3 (15.8%) | 7 (24%) | 0.48 | 5 (9.8%) | 14 (34.1%) | 0.12 |
* Median (25th–75th) ** Frequency expressed as n (percentage).